Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.06 EUR -0.98% Market Closed
Market Cap: 71.6m EUR
Have any thoughts about
Vita 34 AG?
Write Note
Section:
 

Relative Value

The Relative Value of one V3V stock under the Base Case scenario is 5.85 EUR. Compared to the current market price of 4.06 EUR, Vita 34 AG is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

V3V Relative Value
Base Case
5.85 EUR
Undervaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.9
P/S
P/S
Price to Sales
0.9
vs History
98
vs Industry
68
Median 3Y
1.2
Median 5Y
2.5
Industry
2.3
Forward
0.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
-11.3
Median 5Y
-3.7
Industry
23.2
Forward
-49.7
More Details
6.7
P/OCF
P/OCF
Price to OCF
6.7
vs History
79
vs Industry
42
Median 3Y
7.7
Median 5Y
9.3
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-4.8
Industry
20.1
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
53
vs Industry
25
Median 3Y
4.3
Median 5Y
3.4
Industry
2.2
More Details
0.9
EV/S
EV/S
Enterprise Value to Sales
0.9
vs History
98
vs Industry
69
Median 3Y
1.1
Median 5Y
2.2
Industry
2.4
Forward
0.8
More Details
2.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.3
vs History
98
vs Industry
64
Median 3Y
6.4
Median 5Y
4.8
Industry
5
More Details
10.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.2
vs History
46
vs Industry
31
Median 3Y
-4.4
Median 5Y
9.9
Industry
12.8
Forward
9.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-3.4
Industry
17.2
Forward
-111.2
More Details
6.4
EV/OCF
EV/OCF
Enterprise Value to OCF
6.4
vs History
79
vs Industry
44
Median 3Y
7.4
Median 5Y
8.5
Industry
14
More Details
9.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.5
vs History
50
vs Industry
33
Median 3Y
-8.9
Median 5Y
9.6
Industry
18.2
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
96
vs Industry
74
Median 3Y
0.7
Median 5Y
0.9
Industry
1.9
More Details

Multiples Across Competitors

V3V Competitors Multiples
Vita 34 AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Vita 34 AG
XETRA:V3V
70.8m EUR 0.9 -557.3 10.2 -31.8
US
Cigna Group
XMUN:CGN
75.6B EUR 0.3 25.9 8.1 10.4
US
Cigna Corp
NYSE:CI
77.9B USD 0.3 25.6 8 10.3
US
CVS Health Corp
NYSE:CVS
56B USD 0.2 11.2 9.6 9.6
DE
Fresenius Medical Care AG
XMUN:FME
26B EUR 1.3 49 11.2 25.9
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.9B EUR 0.9 -49.2 9.3 19
US
Laboratory Corporation of America Holdings
NYSE:LH
19.3B USD 1.5 44.3 13.2 20.4
US
R1 RCM Inc
NASDAQ:RCM
17.7B USD 7.2 -289.7 38.3 99.1
US
Quest Diagnostics Inc
NYSE:DGX
17.1B USD 1.8 20.4 12.3 16.6
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13B EUR 0.7 24.5 7.1 16.4
US
DaVita Inc
NYSE:DVA
12.7B USD 1 15.4 8 11.1
P/E Multiple
Earnings Growth PEG
DE
Vita 34 AG
XETRA:V3V
Average P/E: 27
Negative Multiple: -557.3 		N/A N/A
US
C
Cigna Group
XMUN:CGN
25.9
25%
1
US
Cigna Corp
NYSE:CI
25.6
25%
1
US
CVS Health Corp
NYSE:CVS
11.2
3%
3.7
DE
Fresenius Medical Care AG
XMUN:FME
49
31%
1.6
DE
Fresenius SE & Co KGaA
XETRA:FRE
Negative Multiple: -49.2 N/A N/A
US
Laboratory Corporation of America Holdings
NYSE:LH
44.3
54%
0.8
US
R1 RCM Inc
NASDAQ:RCM
Negative Multiple: -289.7
253%
N/A
US
Quest Diagnostics Inc
NYSE:DGX
20.4
12%
1.7
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
24.5
31%
0.8
US
DaVita Inc
NYSE:DVA
15.4
17%
0.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Vita 34 AG
XETRA:V3V
Average EV/EBIT: 23.9
Negative Multiple: -31.8 		N/A N/A
US
C
Cigna Group
XMUN:CGN
10.4
10%
1
US
Cigna Corp
NYSE:CI
10.3
10%
1
US
CVS Health Corp
NYSE:CVS
9.6
-1%
N/A
DE
Fresenius Medical Care AG
XMUN:FME
25.9
22%
1.2
DE
Fresenius SE & Co KGaA
XETRA:FRE
19
34%
0.6
US
Laboratory Corporation of America Holdings
NYSE:LH
20.4
25%
0.8
US
R1 RCM Inc
NASDAQ:RCM
99.1
10%
9.9
US
Quest Diagnostics Inc
NYSE:DGX
16.6
11%
1.5
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
16.4
22%
0.7
US
DaVita Inc
NYSE:DVA
11.1
10%
1.1

See Also

Summary
V3V intrinsic value, competitors valuation, and company profile.
DCF Valuation
V3V stock valuation using Discount Cash Flow valuation method.
Relative Valuation
V3V stock valuation using valuation multiples.
Wall Street Estimates
V3V price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
V3V stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.